consists of six institutes of biological products in China, including Chengdu Institute of Biological Products Co.
Plasma Station Distribution of CNBG
Shanghai Institute of Biological Products, 2012
Multiple research institutes operating under the umbrella of CNBG will engage with Aeras on a strategy focused on the joint development, manufacturing and distribution of affordable new TB vaccines for use globally.
As part of this collaboration, Aeras will license its recombinant BCG (rBCG) platform - which aims to improve upon the current TB vaccine - and other technologies to CNBG.
Aeras is excited to expand our relationship with CNBG," said Jim Connolly, President & Chief Executive Officer of Aeras.
At CNBG, we recognize the urgent need to combat tuberculosis and other infectious diseases in both China and around the world," said Xiaoming Yang, President of CNBG.
Operating Income and Total Profit of CNBG
Shanghai Institute of Biological Products, 2007-2008
Pierre Laurin as well as several officials from the CNBG and WIBP organizations.
is one of the subsidiaries of CNBG, has over 50 years experience in the fields of biomedical research and product development; historically strong in R&D, WIBP is the only institute certified by state to offer doctoral program among six Institute of Biological Products in CNBG.
Full scale commercial manufacturing will take place at WIBP initially, could be readily implemented by other affiliated companies within CNBG later, with the goal to achieve a minimum capacity greater than 1.
Lifang Wang, President & Chief Executive Officer of CNBG.